BAFF serum protein and future activity: percentage of visits with future disease activity over the next year by BAFF protein level.
| Variable | Low (<950 pg/mL) N patients=94 N visits=309 | Medium (950–1400 pg/mL) N patients=96 N visits=306 | High (>1400 pg/mL) N patients=96 N visits=303 | p Value | Adjusted p value for age, ethnicity and sex |
|---|---|---|---|---|---|
| PGA >1 | 15 | 16 | 21 | 0.44 | 0.42 |
| SELENA-SLEDAI ≥2 | 51 | 50 | 58 | 0.37 | 0.079 |
| Urine protein:creatinine ratio ≥0.5 | 8 | 7 | 12 | 0.41 | 0.049 |
| Anti-dsDNA ≥10 (Crithidia) | 18 | 12 | 31 | 0.0034 | 0.0022 |
| C3 <79 | 7 | 9 | 19 | 0.035 | 0.059 |
| C4 <79 | 10 | 5 | 17 | 0.016 | 0.026 |
| ESR >20 | 45 | 53 | 54 | 0.37 | 0.30 |
BAFF, B cell activating factor; PGA, physician global assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SELENA, Safety of Estrogens in Lupus Erythematosus: National Assessment.